This study explores the prescribing trends of anti-allergic medications in pediatric healthcare settings, aiming to provide insights into current practices and identify areas for potential improvement. Allergic disorders in children, including allergic rhinitis, asthma, and eczema, require careful management with appropriate pharmacological interventions. However, the patterns and appropriateness of anti-allergic medication use can vary significantly across different clinical environments.

In this study, data were collected from pediatric clinics over a six-month period, focusing on prescriptions of anti-allergic drugs including antihistamines, corticosteroids, and leukotriene receptor antagonists. The analysis involved reviewing patient records to determine the frequency and types of medications prescribed, as well as the adherence to clinical guidelines and recommendations for the management of allergic conditions.

The results revealed a diverse range of prescribing practices across clinics, with notable variations in medication choices and dosages. Antihistamines were the most frequently prescribed drugs, followed by corticosteroids and leukotriene receptor antagonists. The study identified discrepancies between actual prescribing patterns and established guidelines, highlighting areas where adherence to best practices could be improved. Factors such as physician experience, patient demographics, and clinic-specific protocols were found to influence prescribing trends. These findings underscore the need for standardized prescribing practices and continued education for healthcare providers to ensure optimal management of allergic disorders in children. By identifying trends and gaps in current prescribing practices, this study aims to contribute to the development of more effective and evidence-based approaches for treating pediatric allergic conditions.

Brain aging is a complex process characterized by cognitive decline and neuronal deterioration, often exacerbated by oxidative stress and inflammation. D-Galactose-induced brain aging is a widely used model to study these effects. This study investigates the protective effects of Alpinia galanga, a medicinal plant known for its antioxidant and anti-inflammatory properties, against D-Galactose-induced brain aging.

In this study, male Wistar rats were administered D-Galactose to induce brain aging, followed by treatment with Alpinia galanga extract. Behavioral assessments, including memory and cognitive function tests, were conducted to evaluate the impact of the treatment. Additionally, biochemical analyses were performed to measure oxidative stress markers, antioxidant enzyme activities, and inflammatory cytokine levels in the brain.

The results demonstrated that Alpinia galanga significantly improved cognitive function and reduced memory deficits in the D-Galactose-treated rats. Furthermore, the extract effectively decreased oxidative stress markers, enhanced antioxidant enzyme activities, and reduced inflammation in the brain tissue. These findings suggest that Alpinia galanga exerts neuroprotective effects, potentially through its antioxidant and anti-inflammatory properties, thereby mitigating D-Galactose-induced brain aging. This study highlights the therapeutic potential of Alpinia galanga as a natural intervention for combating age-related cognitive decline and offers insights into its mechanisms of action in neuroprotection.